MX2022016179A - Compuestos y metodos para tratar infecciones fungicas. - Google Patents

Compuestos y metodos para tratar infecciones fungicas.

Info

Publication number
MX2022016179A
MX2022016179A MX2022016179A MX2022016179A MX2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A
Authority
MX
Mexico
Prior art keywords
methods
compounds
fungal infections
treating fungal
treating
Prior art date
Application number
MX2022016179A
Other languages
English (en)
Spanish (es)
Inventor
Karen Joy Shaw
Haran Schlamm
Michael R Hodges
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of MX2022016179A publication Critical patent/MX2022016179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022016179A 2020-06-17 2021-06-16 Compuestos y metodos para tratar infecciones fungicas. MX2022016179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040450P 2020-06-17 2020-06-17
PCT/US2021/037578 WO2021257670A1 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Publications (1)

Publication Number Publication Date
MX2022016179A true MX2022016179A (es) 2023-04-20

Family

ID=79268375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016179A MX2022016179A (es) 2020-06-17 2021-06-16 Compuestos y metodos para tratar infecciones fungicas.

Country Status (12)

Country Link
US (1) US20230233586A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167998A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023530936A (cg-RX-API-DMAC7.html)
KR (1) KR20230024375A (cg-RX-API-DMAC7.html)
CN (1) CN115884775A (cg-RX-API-DMAC7.html)
AU (1) AU2021293911B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022024988A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187268A1 (cg-RX-API-DMAC7.html)
IL (1) IL299057A (cg-RX-API-DMAC7.html)
MX (1) MX2022016179A (cg-RX-API-DMAC7.html)
TW (1) TWI888580B (cg-RX-API-DMAC7.html)
WO (1) WO2021257670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010804A (es) * 2020-03-04 2023-01-16 Amplyx Pharmaceuticals Inc Uso de compuestos en el tratamiento de infecciones fungicas.
CN122167488A (zh) * 2024-12-02 2026-06-09 江西科睿药业有限公司 一种抗真菌药物前药、其药物组合物、其中间体、及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
EA202190590A1 (ru) * 2018-08-31 2021-07-16 Ампликс Фармасьютикалз, Инк. Соединения и способы лечения грибковых инфекций
US11819503B2 (en) * 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
MX2022010804A (es) * 2020-03-04 2023-01-16 Amplyx Pharmaceuticals Inc Uso de compuestos en el tratamiento de infecciones fungicas.

Also Published As

Publication number Publication date
BR112022024988A2 (pt) 2022-12-27
EP4167998A4 (en) 2024-07-17
EP4167998A1 (en) 2023-04-26
CA3187268A1 (en) 2021-12-23
CN115884775A (zh) 2023-03-31
JP2023530936A (ja) 2023-07-20
TW202214258A (zh) 2022-04-16
TWI888580B (zh) 2025-07-01
IL299057A (en) 2023-02-01
KR20230024375A (ko) 2023-02-20
US20230233586A1 (en) 2023-07-27
WO2021257670A1 (en) 2021-12-23
AU2021293911B2 (en) 2024-11-14
JP2026123115A (ja) 2026-07-29
AU2021293911A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2022005256A (es) Inhibidores de cd73.
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022000481A2 (es) Inhibidores de enzimas
CL2020001147A1 (es) Compuestos antibacterianos
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CO2026005573A2 (es) Compuestos heterobifuncionales y métodos de tratamiento de enfermedades
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020001808A (es) Nuevos compuestos.
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas